KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vir Biotechnology (VIR) EBT (2018 - 2025)

Historic EBT for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to -$163.0 million.

  • Vir Biotechnology's EBT rose 2368.03% to -$163.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$499.4 million, marking a year-over-year increase of 738.19%. This contributed to the annual value of -$523.1 million for FY2024, which is 1672.87% up from last year.
  • Vir Biotechnology's EBT amounted to -$163.0 million in Q3 2025, which was up 2368.03% from -$110.8 million recorded in Q2 2025.
  • In the past 5 years, Vir Biotechnology's EBT ranged from a high of $921.9 million in Q1 2022 and a low of -$233.7 million during Q2 2022
  • Its 5-year average for EBT is -$12.7 million, with a median of -$120.9 million in 2025.
  • Data for Vir Biotechnology's EBT shows a peak YoY increase of 64642.86% (in 2022) and a maximum YoY decrease of 47778.59% (in 2022) over the last 5 years.
  • Vir Biotechnology's EBT (Quarter) stood at $545.9 million in 2021, then tumbled by 127.78% to -$151.6 million in 2022, then rose by 20.36% to -$120.8 million in 2023, then increased by 13.32% to -$104.7 million in 2024, then tumbled by 55.69% to -$163.0 million in 2025.
  • Its EBT stands at -$163.0 million for Q3 2025, versus -$110.8 million for Q2 2025 and -$120.9 million for Q1 2025.